Play video

Why are recombinant antibodies important in flow cytometry?

Researchers and opinion leaders have considered a number of potential solutions to the so-called antibody-related reproducibility crisis. One is to transition from traditional monoclonal antibodies to recombinant ones.* 

So, what makes recombinant antibodies better and more effective than conventional hybridoma-derived ones? We asked six experts from the flow cytometry and antibody community to share their opinion and experience with recombinant antibodies.  

Six experts. Six perspectivesOne opinion about recombinant antibodies.


“We have seen that there is a huge advantage in terms of the background signal. ”

Dr. Anis Larbi, head of the flow cytometry platform at the A*STAR Institute in Singapore, uses recombinant antibodies in longitudinal studies. Watch the interview to find out why!


“…this is an important gain to improve panel precision and to limit the variability of results being produced.”

Dr. Joffrey de Larichaudy from CELLforCURE, France works in quality control of cellular therapies and he prefers to use recombinant antibodies for flow cytometry. Watch the video and find out why!


“…the whole field is suffering from poor specificity of antibodies.”

NK cell expert Dr. Karl Johan Malmberg from the Oslo University Hospital shares his struggles with conventional antibodies and describes how recombinant antibodies help advance NK cell research. Watch the interview to learn more!


“...approximately 50 % of all antibodies, that are sold, appear not to work.”

Dr. Andrew Bradbury, Chief Scientific Officer at Specifica Inc., is a huge advocate for recombinant antibodies. Watch the interview to find out why he prefers them over traditional hybridoma-derived ones. 


“I strongly believe that in the future, and also now, it really pays off to look at recombinant material.”

The head of the flow cytometry core facility at King’s College London, Dr. Susanne Heck, encourages her users to work with recombinant antibodies. Listen to what she has to say! 


“It´s crucially important for us, that we have high-quality reagents to minimize variation between experiments.”

Transplant immunologist Dr. James Hutchinson has switched from traditional hybridoma-derived antibodies to recombinant ones. Watch the interview to learn more! 

Seems like you are coming from USA!
Do you want to visit our website in your country?